View in EDS HTML Full Text PDF Full Text

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.

Saved in:
Bibliographic Details
Title: Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Authors: Yhim, Ho-Young1, Lee, Na-Ri1, Song, Eun-Kee1, Yim, Chang-Yeol1, Jeon, So Yeon1, Lee, Bohee1, Kim, Jeong-a1, Kim, Hee Sun1, Cho, Eun Hae1, Kwak, Jae-Yong1 jykwak@jbnu.ac.kr
Source: Acta Haematologica. Mar2016, Vol. 135 Issue 3, p133-139. 7p. 1 Diagram, 1 Chart, 2 Graphs.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00015792
DOI:10.1159/000440936